JP2005524670A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524670A5
JP2005524670A5 JP2003574168A JP2003574168A JP2005524670A5 JP 2005524670 A5 JP2005524670 A5 JP 2005524670A5 JP 2003574168 A JP2003574168 A JP 2003574168A JP 2003574168 A JP2003574168 A JP 2003574168A JP 2005524670 A5 JP2005524670 A5 JP 2005524670A5
Authority
JP
Japan
Prior art keywords
hours
carbidopa
time
water contact
rapid release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/006591 external-priority patent/WO2003075893A1/en
Publication of JP2005524670A publication Critical patent/JP2005524670A/ja
Publication of JP2005524670A5 publication Critical patent/JP2005524670A5/ja
Pending legal-status Critical Current

Links

JP2003574168A 2002-03-04 2003-03-03 放出制御投与形態 Pending JP2005524670A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (2)

Publication Number Publication Date
JP2005524670A JP2005524670A (ja) 2005-08-18
JP2005524670A5 true JP2005524670A5 (enExample) 2006-04-13

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574168A Pending JP2005524670A (ja) 2002-03-04 2003-03-03 放出制御投与形態

Country Status (13)

Country Link
EP (1) EP1492508A4 (enExample)
JP (1) JP2005524670A (enExample)
KR (1) KR20100049695A (enExample)
CN (1) CN1649569B (enExample)
AU (2) AU2003217909C1 (enExample)
BR (1) BR0308305A (enExample)
CA (1) CA2477701A1 (enExample)
EA (1) EA005866B1 (enExample)
IL (1) IL163887A0 (enExample)
MX (1) MXPA04008536A (enExample)
NO (1) NO20044188L (enExample)
NZ (1) NZ535083A (enExample)
WO (1) WO2003075893A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
RU2005104827A (ru) * 2002-07-19 2006-07-27 Рэнбакси Лабораториз Лимитед (In) Таблетки суматриптана с замаскированным вкусом и способы их получения
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040122065A1 (en) * 2002-11-12 2004-06-24 Lerner E. Itzhak Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
EP1698448B1 (en) * 2003-11-14 2017-01-18 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing nucleated molding
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CN1921866A (zh) * 2004-02-19 2007-02-28 特瓦制药工业有限公司 使用雷洛昔芬和阿伦膦酸盐的改善的联合治疗
KR100701409B1 (ko) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 호박산 수마트립탄을 함유하는 약제학적 조성물
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
CN103948556A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
CN110604724A (zh) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 一种肠溶美沙拉秦缓释片剂及其制备方法
PE20251521A1 (es) 2022-10-13 2025-06-05 Clarke Mosquito Control Products Inc Composiciones de tabletas insecticidas
JP2024083720A (ja) * 2022-12-12 2024-06-24 パナソニックIpマネジメント株式会社 水処理用徐放性固形薬剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (ja) * 1995-04-03 2007-08-22 中外製薬株式会社 スクラルファート含有製剤組成物
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
SI0931543T1 (en) * 1997-12-19 2002-10-31 Merck Patent Gmbh Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
NZ504834A (en) * 1997-12-22 2001-12-21 Schering Corp Tricyclic amide molecular dispersion composition with enhanced bioavailability
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
MXPA03000194A (es) * 2000-06-28 2004-09-13 Angiogenix Inc Formulaciones de arginina de liberacion controlada.
EA006053B1 (ru) * 2001-12-24 2005-08-25 Тева Фармасьютикал Индастриес Лтд. Твёрдая лекарственная форма, способ её изготовления и устройство

Similar Documents

Publication Publication Date Title
JP2006503588A5 (enExample)
NO2018029I1 (no) Alogliptin i kombinasjon med metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NO20053245D0 (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
JP2006524283A5 (enExample)
JP2007520565A5 (enExample)
JP2004210767A5 (enExample)
JP2003503454A5 (enExample)
JP2005519316A5 (enExample)
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
JP2006507281A5 (enExample)
JP2006516528A5 (enExample)
JP2010507682A5 (enExample)
JP2006517944A5 (enExample)
JP2009538898A5 (enExample)
JP2006506499A5 (enExample)
JP2004534810A5 (enExample)
IT1318376B1 (it) Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo.
RU2002107079A (ru) Вещество, обладающее седативным действием
NO20044188L (no) Kontrollerte frigjoringsdoseformer
JP2002240244A5 (enExample)
JP2008519810A5 (enExample)
JP2007508806A5 (enExample)
JP2005518443A5 (enExample)
RU2003120857A (ru) Адаптогенное средство
JP2004224775A5 (enExample)